Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomecel-B for vaccine response in aging frailty
NCT02982915Phase 2Completed
- Sponsor
- Longeveron
- Start
- Nov 2016
- Primary completion
- Sep 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of laromestrocel in frailty syndrome (5 arms), sponsored by Longeveron. Primary endpoints: Treatment-Emergent Serious Adverse Event at 30 days and Hemagglutination Inhibition Assay at 12 months. Started Nov 2016; status: completed.
02
Drugs
laromestrocel
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT02982915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982915.